Skip to main content
Top
Published in: Clinical Rheumatology 3/2007

01-03-2007 | Original Article

Paraoxonase and arylesterase levels in rheumatoid arthritis

Authors: A. Isik, S. S. Koca, B. Ustundag, H. Celik, A. Yildirim

Published in: Clinical Rheumatology | Issue 3/2007

Login to get access

Abstract

It was reported that lipid peroxidation (LPO) products increase in rheumatoid arthritis (RA) patients and increased LPO products reduce many antioxidants. Lipid hydroperoxides (LOOHs) are byproduct of LPO. Paraoxonase (PON), arylesterase (ARE), free sulfhydryl (SH) groups, and ceruloplasmin (CP) are enzymes or proteins with antioxidant characteristics. This study aims to determine the levels of LOOHs and SH, and the activities of PON1, ARE, and CP in RA patients. The study included 47 active RA cases and 23 healthy volunteers. The levels of LOOHs and SH, and the activities of PON1, ARE, and CP were determined using appropriate methods. Students t test and Spearmans correlation analysis methods were employed in the statistical evaluation. The level of LOOHs was found to be higher (p<0.001), while the level of SH and the activities of PON1, ARE, and CP were found to be lower (p<0.001, <0.001, <0.01, and <0.01, respectively) in the RA patient group when compared with the control group. There was a negative correlation between the level of LOOHs and the activity of PON1 in the patient group (r=−0.420 and p<0.01). The results of our study indicate increased oxidant and decreased antioxidant presence in RA patients. PON1 and ARE are known to have antiatherosclerotic effects in addition to their antioxidant characteristics. As the decrease in these antioxidants, resulting from increased oxidative stress in RA patients, development of atherosclerosis besides tissue injury seems inevitable.
Literature
1.
go back to reference Fox DA (2005) Etiology and pathogenesis of rheumatoid arthritis. In: Koopman WJ, Moreland LW (eds) Arthritis and allied conditions: a textbook of rheumatology, 15th edn. Lippincot Williams and Wilkins, Philadelphia, pp 1089–1115 Fox DA (2005) Etiology and pathogenesis of rheumatoid arthritis. In: Koopman WJ, Moreland LW (eds) Arthritis and allied conditions: a textbook of rheumatology, 15th edn. Lippincot Williams and Wilkins, Philadelphia, pp 1089–1115
2.
go back to reference Jasin HE (2005) Mechanisms of tissue damage in rheumatoid arthritis. In: Koopman WJ, Moreland LW (eds) Arthritis and allied conditions: a textbook of rheumatology, 15th edn. Lippincot Williams and Wilkins, Philadelphia, pp 1141–1164 Jasin HE (2005) Mechanisms of tissue damage in rheumatoid arthritis. In: Koopman WJ, Moreland LW (eds) Arthritis and allied conditions: a textbook of rheumatology, 15th edn. Lippincot Williams and Wilkins, Philadelphia, pp 1141–1164
3.
go back to reference Griffiths HR, Lunec J (1996) The C1q binding activity of IgG is modified in vitro by reactive oxygen species: implications for rheumatoid arthritis. FEBS Lett 388(2–3):161–164PubMedCrossRef Griffiths HR, Lunec J (1996) The C1q binding activity of IgG is modified in vitro by reactive oxygen species: implications for rheumatoid arthritis. FEBS Lett 388(2–3):161–164PubMedCrossRef
4.
go back to reference Nurcombe HL, Bucknall RC, Edwards SW (1991) Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis. Ann Rheum Dis 50(4):237–242PubMed Nurcombe HL, Bucknall RC, Edwards SW (1991) Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis. Ann Rheum Dis 50(4):237–242PubMed
5.
go back to reference Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957–2963PubMedCrossRef Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957–2963PubMedCrossRef
6.
go back to reference Zwerina J, Redlich K, Schett G, Smolen JS (2005) Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci 1051:716–729PubMedCrossRef Zwerina J, Redlich K, Schett G, Smolen JS (2005) Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci 1051:716–729PubMedCrossRef
7.
go back to reference Ridderstad A, Abedi-Valugerdi M, Moller E (1991) Cytokines in rheumatoid arthritis. Ann Med 23(3):219–223PubMed Ridderstad A, Abedi-Valugerdi M, Moller E (1991) Cytokines in rheumatoid arthritis. Ann Med 23(3):219–223PubMed
8.
go back to reference Miesel R, Murphy MP, Kroger H (1996) Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic Res 25(2):161–169PubMed Miesel R, Murphy MP, Kroger H (1996) Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic Res 25(2):161–169PubMed
9.
go back to reference Jaswal S, Mehta HC, Sood AK, Kaur J (2003) Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin Chim Acta 338(1–2):123–129PubMedCrossRef Jaswal S, Mehta HC, Sood AK, Kaur J (2003) Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin Chim Acta 338(1–2):123–129PubMedCrossRef
10.
go back to reference Jira W, Spiteller G, Richter A (1997) Increased levels of lipid oxidation products in low density lipoproteins of patients suffering from rheumatoid arthritis. Chem Phys Lipids 87(1):81–89PubMedCrossRef Jira W, Spiteller G, Richter A (1997) Increased levels of lipid oxidation products in low density lipoproteins of patients suffering from rheumatoid arthritis. Chem Phys Lipids 87(1):81–89PubMedCrossRef
11.
go back to reference Frears ER, Zhang Z, Blake DR, O’Connell JP, Wiynard PG (1996) Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 381(1–2):21–24PubMedCrossRef Frears ER, Zhang Z, Blake DR, O’Connell JP, Wiynard PG (1996) Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 381(1–2):21–24PubMedCrossRef
12.
go back to reference Ozturk HS, Cimen MY, Cimen OB, Kacmaz M, Durak I (1999) Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int 19:35–37PubMedCrossRef Ozturk HS, Cimen MY, Cimen OB, Kacmaz M, Durak I (1999) Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int 19:35–37PubMedCrossRef
13.
go back to reference McKeown MJ, Hall ND, Corvalan JR (1984) Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. Clin Exp Immunol 56(3):607–613PubMed McKeown MJ, Hall ND, Corvalan JR (1984) Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. Clin Exp Immunol 56(3):607–613PubMed
14.
go back to reference Banford JC, Brown DH, Hazelton RA, McNeil CJ, Smith WE, Stturrock RD (1982) Altered thiol status in patients with rheumatoid arthritis. Rheumatol Int 2(3):107–111PubMedCrossRef Banford JC, Brown DH, Hazelton RA, McNeil CJ, Smith WE, Stturrock RD (1982) Altered thiol status in patients with rheumatoid arthritis. Rheumatol Int 2(3):107–111PubMedCrossRef
15.
go back to reference Goldstein IM, Kaplan HB, Edelson HS, Weissmann G (1979) Ceruloplasmin. A scavenger of superoxide anion radicals. J Biol Chem 254(10):4040–4045PubMed Goldstein IM, Kaplan HB, Edelson HS, Weissmann G (1979) Ceruloplasmin. A scavenger of superoxide anion radicals. J Biol Chem 254(10):4040–4045PubMed
16.
17.
go back to reference Kiziltunc A, Cogagil S, Cerrahoglu L (1998) Carnitine and antioxidants levels in patients with rheumatoid arthritis. Scand J Rheumatol 27(6):441–445PubMedCrossRef Kiziltunc A, Cogagil S, Cerrahoglu L (1998) Carnitine and antioxidants levels in patients with rheumatoid arthritis. Scand J Rheumatol 27(6):441–445PubMedCrossRef
18.
go back to reference Dogan P, Tanrikulu G, Soyuer U, Kose K (1994) Oxidative enzymes of polymorphonuclear leucocytes and plasma fibrinogen, ceruloplasmin, and copper levels in Behcet’s disease. Clin Biochem 27(5):413–418PubMedCrossRef Dogan P, Tanrikulu G, Soyuer U, Kose K (1994) Oxidative enzymes of polymorphonuclear leucocytes and plasma fibrinogen, ceruloplasmin, and copper levels in Behcet’s disease. Clin Biochem 27(5):413–418PubMedCrossRef
19.
go back to reference Gutteridge JM, Winyard PG, Blake DR, Lunec J, Brailsford S, Halliwell B (1985) The behaviour of caeruloplasmin in stored human extracellular fluids in relation to ferroxidase II activity, lipid peroxidation and phenanthroline-detectable copper. Biochem J 230(2):517–523PubMed Gutteridge JM, Winyard PG, Blake DR, Lunec J, Brailsford S, Halliwell B (1985) The behaviour of caeruloplasmin in stored human extracellular fluids in relation to ferroxidase II activity, lipid peroxidation and phenanthroline-detectable copper. Biochem J 230(2):517–523PubMed
20.
go back to reference Mackness B, Durrington PN, Mackness MI (1998) Human serum paraoxonase. Gen Pharmacol 31(3):329–336PubMedCrossRef Mackness B, Durrington PN, Mackness MI (1998) Human serum paraoxonase. Gen Pharmacol 31(3):329–336PubMedCrossRef
21.
go back to reference Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21(4):473–480PubMed Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21(4):473–480PubMed
22.
go back to reference Mackness MI, Mackness B, Durrington PN (2003) Paraoxonase and coronary heart disease. Atheroscler Suppl 3(4):49–55CrossRef Mackness MI, Mackness B, Durrington PN (2003) Paraoxonase and coronary heart disease. Atheroscler Suppl 3(4):49–55CrossRef
23.
go back to reference Arnet FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324 Arnet FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324
25.
go back to reference Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B (1993) Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 121(2):257–262PubMed Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B (1993) Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 121(2):257–262PubMed
26.
go back to reference La Du BN, Eckerson HW (1984) The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed Proc 43:2338–2341PubMed La Du BN, Eckerson HW (1984) The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed Proc 43:2338–2341PubMed
27.
go back to reference Sunderman FW, Nomoto S (1970) Measurement of human serum ceruloplasmin by its p-phenylenediamine oxidase activity. Clin Chem 16(11):903–910PubMed Sunderman FW, Nomoto S (1970) Measurement of human serum ceruloplasmin by its p-phenylenediamine oxidase activity. Clin Chem 16(11):903–910PubMed
28.
go back to reference Erel O (1998) Automated measurement of serum ferroxidase activity. Clin Chem 44(11):2313–2319PubMed Erel O (1998) Automated measurement of serum ferroxidase activity. Clin Chem 44(11):2313–2319PubMed
29.
go back to reference Gorog P, Kotak DC, Kovacs IB (1991) Simple and specific test for measuring lipid peroxides in plasma. J Clin Pathol 44(9):765–767PubMed Gorog P, Kotak DC, Kovacs IB (1991) Simple and specific test for measuring lipid peroxides in plasma. J Clin Pathol 44(9):765–767PubMed
30.
go back to reference Pinals RS, Masi AT, Larsen RA (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24(10):1308–1315PubMed Pinals RS, Masi AT, Larsen RA (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24(10):1308–1315PubMed
31.
go back to reference Symmons DP, Jones MA, Scott DL, Prior P (1998) Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25:1072–1077PubMed Symmons DP, Jones MA, Scott DL, Prior P (1998) Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25:1072–1077PubMed
32.
go back to reference Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46(4):862–873PubMedCrossRef Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46(4):862–873PubMedCrossRef
33.
go back to reference Gutteridge JM (1985) Inhibition of the Fenton reaction by the protein caeruloplasmin and other copper complexes. Assessment of ferroxidase and radical scavenging activities. Chem Biol Interact 56(1):113–120PubMedCrossRef Gutteridge JM (1985) Inhibition of the Fenton reaction by the protein caeruloplasmin and other copper complexes. Assessment of ferroxidase and radical scavenging activities. Chem Biol Interact 56(1):113–120PubMedCrossRef
34.
go back to reference Louro MO, Cocho JA, Mera A, Tutor JV (2000) Immunochemical and enzymatic study of ceruloplasmin in rheumatoid arthritis. J Trace Elem Med Biol 14(3):174–178PubMedCrossRef Louro MO, Cocho JA, Mera A, Tutor JV (2000) Immunochemical and enzymatic study of ceruloplasmin in rheumatoid arthritis. J Trace Elem Med Biol 14(3):174–178PubMedCrossRef
35.
go back to reference Gambhir JK, Lali P, Jain AK (1997) Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin Biochem 30(4):351–355PubMedCrossRef Gambhir JK, Lali P, Jain AK (1997) Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin Biochem 30(4):351–355PubMedCrossRef
36.
go back to reference Hall ND, Maslen CL, Blake DR (1984) The oxidation of serum sulph-hydryl groups by hydrogen peroxide secreted by stimulated phagocytic cells in rheumatoid arthritis. Rheumatol Int 4(1):35–38PubMedCrossRef Hall ND, Maslen CL, Blake DR (1984) The oxidation of serum sulph-hydryl groups by hydrogen peroxide secreted by stimulated phagocytic cells in rheumatoid arthritis. Rheumatol Int 4(1):35–38PubMedCrossRef
37.
go back to reference Hall ND, Blake DR, Bacon PA (1982) Serum sulphydryl levels in early synovitis. J Rheumatol 9(4):593–596PubMed Hall ND, Blake DR, Bacon PA (1982) Serum sulphydryl levels in early synovitis. J Rheumatol 9(4):593–596PubMed
38.
go back to reference Giustarini D, Lorenzini S, Rossi R, Chindamo D, Di Simplicio P, Marcolongo R (2005) Altered thiol pattern in plasma of subjects affected by rheumatoid arthritis. Clin Exp Rheumatol 23(2):205–212PubMed Giustarini D, Lorenzini S, Rossi R, Chindamo D, Di Simplicio P, Marcolongo R (2005) Altered thiol pattern in plasma of subjects affected by rheumatoid arthritis. Clin Exp Rheumatol 23(2):205–212PubMed
39.
go back to reference Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S et al (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394(6690):284–287PubMedCrossRef Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S et al (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394(6690):284–287PubMedCrossRef
40.
go back to reference Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K et al (2003) Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 72(25):2877–2885PubMedCrossRef Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K et al (2003) Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 72(25):2877–2885PubMedCrossRef
41.
go back to reference Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D et al (2005) Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem 38(10):951–955PubMedCrossRef Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D et al (2005) Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem 38(10):951–955PubMedCrossRef
42.
go back to reference Maury CP, Junge W, Teppo AM (1984) Serum esterase activity in reactive systemic amyloidosis and its relation to amyloid A degrading activity. J Lab Clin Med 104(5):761–766PubMed Maury CP, Junge W, Teppo AM (1984) Serum esterase activity in reactive systemic amyloidosis and its relation to amyloid A degrading activity. J Lab Clin Med 104(5):761–766PubMed
43.
go back to reference Feingold KR, Menon RA, Moser AH, Grunfeld C (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139(2):307–315PubMedCrossRef Feingold KR, Menon RA, Moser AH, Grunfeld C (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139(2):307–315PubMedCrossRef
44.
go back to reference Kumon Y, Nakauchi Y, Suehiro T, Shiinoki T, Tanimoto N, Inoue M et al (2002) Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid 9(3):160–164PubMed Kumon Y, Nakauchi Y, Suehiro T, Shiinoki T, Tanimoto N, Inoue M et al (2002) Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid 9(3):160–164PubMed
45.
go back to reference Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M et al (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18(10):1617–1624PubMed Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M et al (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18(10):1617–1624PubMed
46.
go back to reference Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL et al (1999) Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26:892–904PubMedCrossRef Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL et al (1999) Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26:892–904PubMedCrossRef
Metadata
Title
Paraoxonase and arylesterase levels in rheumatoid arthritis
Authors
A. Isik
S. S. Koca
B. Ustundag
H. Celik
A. Yildirim
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0300-8

Other articles of this Issue 3/2007

Clinical Rheumatology 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.